Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.
Journal: Bone marrow transplantation
Published: January 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
Journal: American journal of hematology
Published: October 28, 2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?
Journal: Immunotherapy
Published: October 17, 2025
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review.
Journal: Expert opinion on investigational drugs
Published: May 27, 2025
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.
Journal: Bone marrow transplantation
Published: November 26, 2024
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Journal: Bone marrow transplantation
Published: October 18, 2024
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.
Journal: Current hematologic malignancy reports
Published: July 31, 2024
Last Updated: 09/26/2026